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Circulation
ORIGINAL RESEARCH ARTICLE

Prospective Validation of the Emergency
Heart Failure Mortality Risk Grade for Acute
Heart Failure
The ACUTE Study
Editorial, see p 1157
BACKGROUND: Improved risk stratification of acute heart failure in the
emergency department may inform physicians’ decisions regarding patient
admission or early discharge disposition. We aimed to validate the previouslyderived Emergency Heart failure Mortality Risk Grade for 7-day (EHMRG7) and
30-day (EHMRG30-ST) mortality.
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METHODS: We conducted a multicenter, prospective validation study of patients
with acute heart failure at 9 hospitals. We surveyed physicians for their estimates
of 7-day mortality risk, obtained for each patient before knowledge of the
model predictions, and compared these with EHMRG7 for discrimination and net
reclassification improvement. We also prospectively examined discrimination of
the EHMRG30-ST model, which incorporates all components of EHMRG7 as well
as the presence of ST-depression on the 12-lead ECG.
RESULTS: We recruited 1983 patients seeking emergency department care
for acute heart failure. Mortality rates at 7 days in the 5 risk groups (very low,
low, intermediate, high, and very high risk) were 0%, 0%, 0.6%, 1.9%, and
3.9%, respectively. At 30 days, the corresponding mortality rates were 0%,
1.9%, 3.9%, 5.9%, and 14.3%. Compared with physician-estimated risk of
7-day mortality (PER7; c-statistic, 0.71; 95% CI, 0.64–0.78) there was improved
discrimination with EHMRG7 (c-statistic, 0.81; 95% CI, 0.75–0.87; P=0.022
versus PER7) and with EHMRG7 combined with physicians’ estimates (c-statistic,
0.82; 95% CI, 0.76–0.88; P=0.003 versus PER7). Model discrimination
increased nonsignificantly by 0.014 (95% CI, −0.009–0.037) when physicians’
estimates combined with EHMRG7 were compared with EHMRG7 alone
(P=0.242). The c-statistic for EHMRG30-ST alone was 0.77 (95% CI, 0.73–
0.81) and 30-day model discrimination increased nonsignificantly by addition
of physician-estimated risk to 0.78 (95% CI, 0.73–0.82; P=0.187). Net
reclassification improvement with EHMRG7 was 0.763 (95% CI, 0.465–1.062)
when assessed continuously and 0.820 (0.560–1.080) using risk categories
compared with PER7.
CONCLUSIONS: A clinical model allowing simultaneous prediction of mortality
at both 7 and 30 days identified acute heart failure patients with a low risk of
events. Compared with physicians’ estimates, our multivariable model was better
able to predict 7-day mortality and may guide clinical decisions.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique
identifier: NCT02634762.
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What Is New?
• In this prospective, multicenter, real-world study of
1983 acute heart failure patients presenting to the
emergency department, we found that the Emergency Heart failure Mortality Risk Grade (EHMRG7)
stratified the risk of 7-day mortality, and was better
able to predict risk than physicians’ estimates.
• Seven-day mortality rates were 0%, 0%, 0.6%,
1.9%, and 3.9% in those at very low, low, intermediate, high, and very high risk.
• The EHMRG30-ST model was able to simultaneously predict 30-day risk in heart failure patients,
enabling identification of a very low risk patient
subgroup at both time points.

What Are the Clinical Implications?
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• Paradoxically, physicians estimated that lower-risk
patients would have higher mortality, and that the
highest-risk group would have better survival than
was observed.
• This may explain, in part, our earlier observations
that reliance on clinically judged risk estimates
alone may result in a potential mismatch, whereby
many low-risk patients are hospitalized or, conversely, potentially unsafe discharges from the
emergency department might occur.
• The EHMRG models provide physicians important
prognostic information that complements clinical judgment in the decision to admit or perform
early discharge of patients from the hospital or the
emergency department.

H

eart failure (HF) is a leading cause of hospitalization in North America, with substantial health
economic impacts.1 Patients with acute HF often
present to the emergency department for care, and in
some cases patients are admitted to hospital based not
on symptoms but rather because of the unknown risk
of clinical instability.2 There has been a slight decline
in hospitalizations for HF in recent decades; however,
emergency department visits for this condition have
not decreased significantly.3–5 Up to 15% of acute HF
patients who present to an emergency department in
the United States are discharged home directly, but
this proportion has not changed appreciably over time
and varies between academic and community hospitals partly because of patient complexity.5,6 However, in
the absence of validated methods for risk stratification,
some high-risk patients will be discharged home and
may subsequently die despite having been considered
safe to discharge.7 Conversely, many-low risk patients
are admitted to hospital, leading to inefficient use of
scarce healthcare resources and exposure to adverse events related to hospitalization.2
Circulation. 2019;139:1146–1156. DOI: 10.1161/CIRCULATIONAHA.118.035509

METHODS
Patients
At 9 hospitals in Ontario, Canada from July 2010 to March
2015, patients presenting to the emergency department with
HF were recruited (Table I in the online-only Data Supplement).
We included those with acute HF diagnosed clinically as suggested by national guidelines published by the Canadian
Cardiovascular Society and the Framingham criteria (90% sensitivity for acute HF). Acute HF was confirmed using (1) final
primary diagnosis of ICD-10 code I50 in the discharge abstracts
of the hospital or the emergency department (95% specificity
for acute HF) and (2) entry into the Ontario HF Cohort, which
has been validated against electronic medical records (84.8%
sensitivity, 97.0% specificity). B-type natriuretic peptide was
not required for diagnosis, but could be used if deemed clinically necessary. Research Ethics Board approval was obtained
from all participating sites before study initiation. Participating
Research Ethics Boards waived the requirement for informed
consent for this study because it posed minimal risk to participants and challenges in obtaining consent from acutely ill HF
patients in the emergency setting. Therefore, we were able to
include all patients irrespective of language spoken and ethnicity. Those who were palliative or had do not resuscitate orders on arrival were also excluded, as they were not included
in the aforementioned studies. We also excluded patients who
were dialysis dependent because the pathophysiology and
management of acute HF is different in these patients. The
methodology of the ACUTE study (Acute Congestive Heart
February 26, 2019
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Clinical Perspective

Accurate prognostic information may enhance our
ability to predict outcomes, thus informing disposition
decisions for patients with acute HF after presentation
to the emergency department.8 Specifically, higher-risk
patients would be hospitalized to facilitate more timely
investigations and medical optimization, whereas lower-risk patients could be discharged earlier than routinely performed. Similar approaches to hospitalization
decisions for pneumonia have resulted in increased
early discharge rates and patient satisfaction, with no
change in mortality.9 However, few similar risk models
have been prospectively validated in acute HF, and none
have been compared with physicians’ estimates of risk.
We previously derived and internally validated the Emergency Heart failure Mortality Risk Grade (EHMRG7)
for prediction of 7-day risk.10 Furthermore, we extended
the model to predict 30-day mortality (EHMRG30-ST)
by inclusion of one additional variable, the presence of
ST-segment depression on the 12-lead ECG.11 The primary objectives of this study were to (1) prospectively
evaluate the performance of EHMRG7 in a new cohort
of patients seeking care in the emergency department,
and (2) compare the model with physicians’ estimates
of 7-day mortality risk. Our secondary objective was to
examine the performance of EHMRG30-ST in the same
prospective cohort. We hypothesized that the multivariable risk score would have superior predictive accuracy
compared with physician-estimated risk.

ORIGINAL RESEARCH
ARTICLE
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Failure Urgent Care Evaluation) and details of the physician
survey have been previously published and registered (URL:
www.clinicaltrials.gov. Unique identifier: NCT02634762).12 The
data, analytic methods, and study materials will not be made
available to other researchers for purposes of reproducing the
results or replicating the procedure, because of privacy laws.

Data Entry and Physician Survey

Downloaded from http://ahajournals.org by on June 22, 2022

During the study period, the variables needed to determine the
EHMRG7 risk score were entered into a computer-based calculator by a physician, nurse, or research assistant in the emergency department. Data entry and the survey were performed
after the necessary laboratory tests were completed and after
reassessing the patient’s response to diuretic therapy, but before
the physician rendered a disposition decision about admission
or discharge from the emergency department (see Table 1 for
list of variables). Before the EHMRG7 risk score was displayed,
the physician responsible for emergency department disposition was required to estimate the probability that the patient
would die within 7 days and enter their proposed management
plan for the patient. They were required to enter their physician-estimated risk both as a percentage (from 0–100%) and
as a category of risk: very low, low, intermediate, high, or very
high risk as previously described.12 The EHMRG7 score could
not be calculated unless the physician-estimated risk survey was
completed, so that their estimates could not be influenced by
the results display. Information about the ACUTE study was presented at departmental meetings and in the emergency department (eg, data entry, calculation of risk score), but individual
physician participation in patient recruitment was voluntary.
The treating physicians were encouraged to make admission/
discharge decisions as per usual, and not base any admission or
treatment decisions on the EHMRG7 score. In addition to the
above, we collected the unique hospital medical record number,
date of visit, and sex of the patient for probabilistic linkage. All
data were then securely transferred using a virtual private network connection to the ICES for storage.

Risk Prediction
The EHMRG7 risk score was determined using previously
published methods, and was available to the emergency department physician.10 We also determined the EHMRG30-ST
risk probability in patients who had a 12-lead ECG performed, as previously published (see Table 1).11 The 12-lead
ECG was abstracted using a standardized data collection
form as described previously.13 The 7-day risk score was not
modified in this study and the previously-published 30-day
EHMRG30-ST coefficients were used, without further refitting
or recalibration, to determine how the originally published
models performed.10,11 Consequently, we used previously
published thresholds to divide patients into 5 risk groups, and
subdivided the highest risk group into 2 highest risk deciles
based on previous decile thresholds (groups 5a and 5b).

Validation of EHMRG for Acute Heart Failure

department visits in the Province of Ontario, to determine their
unique encoded health card number. We subsequently linked
each patient with the Registered Persons Database to determine
mortality and the Canadian Institute for Health Information
Discharge Abstract Database to determine (1) admission to hospital or discharge home from the emergency department, (2)
intubation or noninvasive positive pressure ventilation in hospitalized patients, and (3) hospital length-of-stay.14–16

Outcomes
The primary outcome was death within 7 days after presentation to the emergency department. Mortality within 30 days
after emergency presentation was a secondary outcome. We
considered mortality prediction to be important because it
forms the foundation for future studies of nonfatal outcomes
(eg, hospital readmissions and return emergency visits) as a
competing risk.

Statistical Analysis
Continuous variables were summarized as medians with interquartile ranges. Categorical variables were presented as
proportions and compared using the χ2 statistic. To compare
physician-estimated risk and EHMRG7, we (1) calculated the
Spearman rank correlation, and (2) standardized both scores
to have a mean of 0 and variance of 1 and examined the
β-coefficient from a logistic regression model for the outcome
of death for 1 SD increase in the standardized scores. Using
previously-published thresholds for different quintiles of risk,
odds ratios and 95% confidence intervals (CIs) for 7-day and
30-day mortality were determined for each increasing risk category or score. We also used logistic regression to determine
the effect on mortality of increasing physician-estimated and
EHMRG-predicted risks of death. Shrinkage estimators were
used to determine that there was no model overfit.
We compared the EHMRG7 and physician-estimated risk
using areas under the receiver operating characteristic curves
and compared predicted rates using the sign test. We examined the impact of EHMRG7 in 2 ways. First, we identified the
proportion of patients in whom the physician-judged decision
to admit or discharge would have been changed if EHMRG7
was used to guide decisions. Specifically, we counted the
Table 1. Variables in the EHMRG 7-Day and 30-Day Risk Models
Age*
Arrival by ambulance*
Systolic blood pressure (triage)†
Heart rate (triage)†
Oxygen saturation (triage)†
Potassium concentration*
Creatinine concentration*
Troponin*
Active cancer*

Data Sources and Linkage

Metolazone use prior to ED arrival*

Data linkage techniques have been reported elsewhere.12
In summary, we cross-indexed the prospectively-identified
patient’s medical record number with the National Ambulatory
Care Reporting System, which contains records of all emergency

ST-depression on 12-lead ECG (30-day model only)*
*Obtained from the electronic medical record in the emergency or face
sheet.
†Obtained from nurse at initial triage on arrival to emergency.
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RESULTS
Patient Characteristics and Outcomes
Characteristics of the 1983 unique patients enrolled in
this prospective study are shown in Table 2. A flow diagram of exclusion criteria for the study cohort is shown
in Figure 1. Among the study cohort, 88.5% met ICD10 discharge criteria for acute HF and 94.6% met the
HF entry criteria into the Ontario HF Cohort.20,21 Characteristics of nonstudy HF patients in the population are
shown in Table II in the online-only Data Supplement.
Variables for determination of the 7- and 30-day risk
models are shown in Table 3. Among the study cohort, 1566 (79%) were admitted from the emergency
department. There were 39 deaths at 7 days and 138
deaths (121 in-hospital and 17 out-of-hospital) at 30
days. Intubation or noninvasive positive pressure ventilation occurred in 83 (5.3%) hospitalized patients.

Risk of Death According to PhysicianEstimated Risk or Model Predictions
Stratifying by risk categories, there were no deaths in
the 2 lowest EHMRG7 risk groups at 7-day follow-up
(Figure 2). There were also no deaths in the lowest risk
Circulation. 2019;139:1146–1156. DOI: 10.1161/CIRCULATIONAHA.118.035509

Table 2. Cohort Characteristics
Characteristic
N
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number of additional discharges from the emergency department if all low-/very low–risk patients were discharged,
and the number of excess hospital admissions if all high-/
very high–risk patients were admitted, compared with the
physicians’ original management plan before knowledge of
the EHMRG risk result. Second, we examined continuous and
categorical net reclassification improvement of the EHMRG
model and physician-estimated risk combined compared with
physician estimation alone for 7- and 30-day outcomes.17
We examined factors associated with hospital admission
using univariate and multiple logistic regression analyses. The
following factors were included in the model: age, sex, diuretic
given in the emergency department, symptomatic improvement with diuretic, and 1 SD increase in physician-estimated
risk and EHMRG7 scores. Although ACUTE was a single-arm
study, to provide context and estimate how our study cohort
compared with the general population of HF patients who
visited the emergency department, we examined those with a
primary International Statistical Classification of Diseases and
Related Health Problems, Tenth Revision, Canada (ICD-10-CA)
diagnosis code I50 using the National Ambulatory Care
Reporting System during similar years of the study at participating hospitals. Comorbidities, including previous HF or myocardial infarction, diabetes mellitus, hypertension, ischemic
heart disease, atrial fibrillation, and other noncardiac comorbidities, were identified using published methods.14,18–20 In our
logistic regression models, calibration was assessed using the
Hosmer–Lemeshow statistic. Model performance was evaluated using the c-statistic and the Brier score. Analyses were
performed using SAS version 9.4 (SAS Institute, Inc., Cary,
NC). P values < 0.05 were considered statistically significant.

Validation of EHMRG for Acute Heart Failure

Study Cohort
1983

Demographics
 Age, median (IQR)

81 (71, 87)

 Men, n (%)

1032 (52.0%)

 Previous HF diagnosis*

1422 (71.7%)

Risk factors
 Diabetes mellitus*

1050 (53.0%)

 Hypertension*

1784 (90.0%)

Cardiac etiologic conditions
 Previous MI‡
 Previous ischemic heart disease†

418 (21.1%)
1015 (51.2%)

 Valvular heart disease

211 (10.6%)

 Previous atrial fibrillation†

776 (39.1%)

Noncardiac comorbidities
 CVD‡

236 (11.9%)

 COPD‡

502 (25.3%)

 Dementia‡

147 (7.4%)

 Renal disease‡

386 (19.5%)

 Any cancer‡

173 (8.7%)

COPD indicated chronic obstructive pulmonary disorder; CVD, cardiovascular
disease; HF, heart failure; and MI, myocardial infarction.
*Ambulatory or inpatient diagnoses from the Ontario diabetes mellitus,
hypertension, or heart failure databases.20
†Ambulatory or inpatient diagnoses for ischemic heart disease18 or atrial
fibrillation19 within 3 years before emergency presentation
‡Comorbidity diagnosis based on Charlson classification system within 3
years before emergency presentation using the Canadian Institute for Health
Information or National Ambulatory Care Reporting System databases.

EHMRG30-ST risk group at 30-day follow-up (Figure 2).
The median EHMRG7 scores were 46 (interquartile
range [IQR], −6 to 96) and −11 (IQR, −46 to 32) among
those who were admitted and discharged, respectively.
Median predicted risks of 30-day death were 8% (IQR,
4% to 17%) for admitted and 4% (IQR, 2% to 7%) for
patients discharged from the emergency department
(P<0.001). Observed mortality rates were 2.4% (7-day)
and 7.7% (30-day) for admitted, and <1.5% (7-day)
and 3.3% (30-day) for discharged patients. The odds
ratio for 7-day mortality was 1.41 (95% CI, 1.21–1.60)
for a 1-SD (1-SD = 7.9%) increase in the physician-estimated risk and 1.54 (95% CI, 1.28–1.81) for a 10%
increase in physician-estimated risk. The odds ratio
for 7-day death was 2.94 (95% CI, 2.17–4.03) for a
1-SD (1-SD = 73.3 points) increase in the unstandardized EHMRG7 score and 2.48 (95% CI, 1.87–3.27) for
a 10% (equivalent to 61.7 points) increase in the predicted risk of 7-day death.
When the cohort was stratified by the 5 EHMRG30ST risk strata (with the highest stratum being further
divided into 2 substrata), there was early separation of
survival curves over 30 days of follow-up, with particFebruary 26, 2019
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30-day models were 0.98 and 0.99, indicating no model
overfit. Calibration plots of observed versus predicted
7-day and 30-day mortality are shown in Figures II and III
in the online-only Data Supplement, respectively.

Net Reclassification Improvement

Figure 1. Patient flow diagram.
EHMRG7 indicates Emergency Heart failure Mortality Risk Grade for 7-day
mortality; EHMRG30-ST, Emergency Heart failure Mortality Risk Grade for
30-day mortality with ST-segment depression; IKN, ICES Key Number; NACRS,
National Ambulatory Care Reporting System; and PER7, physician-estimated
risk of 7-day mortality.

Downloaded from http://ahajournals.org by on June 22, 2022

ularly high risk observed in categories 5a and 5b (Figure 3). The EHMRG30-ST model demonstrated nonlinearity for the outcome of the log odds of 30-day
mortality, therefore a logit transformation was performed. After logit transformation, the odds ratio for
30-day death was 2.93 (95% CI, 2.39–3.63) for a 1-SD
(1-SD = 1.21) increase and 2.43 (95% CI, 2.05–2.89)
for a 1-unit increase in the logit EHMRG30-ST.

Model Performance

Using a category-free approach, the net reclassification improvement was 0.763 (95% CI, 0.465–1.062)
for EHMRG7 combined with physician-estimated risk
compared with PER7 alone. Using categories of risk
based on groups 1, 2, 3, 4, 5a, and 5b, categorical
net reclassification improvement was 0.820 (95% CI,
0.560–1.080) when using EHMRG7 score combined
with physician-estimated risk compared with PER7 alone (Table III in the online-only Data Supplement).
Net reclassification improvement was 0.308 (95% CI,
0.050–0.566) for those with events and 0.512 (95% CI,
0.480–0.545) for those without events (Tables IV and
V in the online-only Data Supplement, respectively).
The integrated discrimination improvement was 0.030
overall, 0.029 for events, and −0.001 for nonevents.
Comparing EHMRG7 alone to PER7 alone, overall net
reclassification improvement was similarly high: 0.718
(95% CI, 0.453–0.984). The improvement in reclassification was high in those without events: 0.462 (95%
CI, 0.428–0.496), as shown in Table IV in the onlineonly Data Supplement.
Table 3. EHMRG Variables
Variable

Median (IQR) or n (%)

N

1983

Age, y

81 (71, 87)

Arrival by ambulance

864 (43.6%)

Triage SBP, mm Hg

136 (119, 155)

The c-statistic for prediction of 7-day mortality using the
physician-estimated risk was 0.71 (95% CI, 0.64–0.78).
EHMRG7 demonstrated superior discrimination with a
c-statistic of 0.81 (95% CI, 0.75–0.87), which was significantly improved compared with physician-estimated
risk (P=0.022). When both physician-estimated risk and
EHMRG7 were combined together in the same model,
the c-statistic was 0.82 (95% CI, 0.76–0.88), which was
superior to physician-estimated risk alone (P=0.003),
but was not significantly different from EHMRG7 alone
(P=0.242). Receiver operating curves are shown in Figure I in the online-only Data Supplement. Prediction of
30-day mortality for logit-transformed EHMRG30-ST exhibited a c-statistic of 0.77 (95% CI, 0.73–0.81). There
was no lack of model fit as demonstrated by Hosmer–
Lemeshow statistic P values > 0.1 for all EHMRG models
with or without physician estimated risk. The Brier scores
were 0.019 and 0.059 for the 7- and 30-day models, respectively. The shrinkage estimators for the 7-day and

EHMRG indicates Emergency Heart failure Mortality Risk Grade; LBBB, left
bundle branch block; LVH, left ventricular hypertrophy; IQR, interquartile range;
and ULN, upper limit of normal.
*Based on n=1805.
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Triage heart rate, bpm
Triage O2 saturation, %
Creatinine concentration, mg/dL

84 (72, 101)
96 (93, 98)
1.18 (0.89, 1.69)

Potassium concentration
< 4.0 mEq/L

583 (29.4%)

 4.0 to 4.5 mEq/L

787 (39.7%)

 > 4.5 mEq/L

613 (30.9%)

Troponin, >ULN

686 (34.6%)

Active cancer

142 (7.2%)

Metolazone

69 (3.5%)

ST-depression on ECG

*

Absent

928 (51.4%)

 Present

225 (12.5%)

 Other (LBBB, paced, LVH)

652 (36.1%)

Lee et al
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Comparison of Physician-Estimated Risk
With EHMRG7
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As shown in the scatterplot, there was low correlation
between the predicted probability of 7-day death using
the EHMRG7 and physician-estimated risk (Figure IV in
the online-only Data Supplement). Physician-estimated
risk was higher than the mean predicted risk across the
deciles of the EHMRG7 model for the lowest 9 deciles
of risk (Figure 4). In contrast, physician estimates underestimated risk in the highest EHMRG7 decile (6.4 versus 10.4%). In the lowest 4 deciles, physician-estimated risk ranged from 2.1% to 3.1%, and was 2.5% to
3.2% in deciles 5 to 7 (Figure 4). With the exception of
decile 8 (P=0.455), comparisons were statistically significant for all deciles comparing physician-estimated risk
with EHMRG7 (all P<0.001).

Physician Survey
The response rate to the physician survey was 100%
because it was required before entering the risk score
(Table 4). The majority of patients were given furosemide, and approximately one-third were considered to
have improved while being observed in the emergency
department. In 1561 (78.7%) patients, the plan was to
admit the patient either directly or after specialist referral (Table 4). Physicians preferred outpatient follow-up
with a cardiologist or the heart function clinic in the
majority of cases.
Results of the survey stratified by the EHMRG7 score,
and the ultimate disposition of patients from the emergency department, are shown in Table VII in the onlineonly Data Supplement. Of the 400 patients in whom
the plan was to ultimately discharge home, 131 were
high or very high risk according to the EHMRG7 score,
but only 24 were admitted to hospital. Conversely,
although 186 of the patients initially planned for disCirculation. 2019;139:1146–1156. DOI: 10.1161/CIRCULATIONAHA.118.035509

charge were very low or low risk, 20 were still admitted to hospital. Of the 1571 patients in whom the plan
was to admit to hospital from the emergency department, 332 were low or very low risk. Of these, 310
(93.4%) were admitted to hospital. If decisions to admit or discharge were purely guided by EHMRG7 such
that all high-/very high–risk patients were admitted and
all low-/very low–risk patients were discharged, hospital admissions could have been reduced by as much as
9.8% (Table VII in the online-only Data Supplement).
Predictors associated with hospital admission are
shown in Table 5. On multivariable analysis, use of diuretics was associated with increased odds of admission, whereas perceived improvement with furosemide
was associated with decreased odds of hospital admission. Higher physician-estimated risk and EHMRG7
scores were associated with higher likelihood of hospitalization per 1-SD increment. Among those who
were admitted to hospital, higher-risk patients had significantly longer lengths of hospital stay: 7 (IQR, 4–13)
days for very high (P<0.001) and 6 (IQR, 3–12) days for
high risk (P=0.044) compared with 5 days for intermediate risk (IQR, 3–9 days). Length of hospital stay for
low- (6 [IQR, 3–11] days) and very low– (5 [IQR, 3–8]
days) risk groups did not differ from those who were at
intermediate risk (P=0.135 and P=0.213, respectively).

Estimation of Simultaneous 7-Day and
30-Day Mortality Risks
Simultaneous 7-day risk scores (x axis) and 30-day risk (y
axis) are shown in Figure V in the online-only Data Supplement for the current prospective validation cohort
(red x). For comparison, a similar scatterplot is presented
for the previously published original derivation cohort
(background, blue square), demonstrating that the risk
distributions of the 2 cohorts overlap, without a systematically higher or lower risk in the validation cohort.10
February 26, 2019
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Figure 2. Mortality rates by EHMRG7 or
EHMRG30-ST risk categories.
Risk categories: 1 = very low, 2 = low, 3 = intermediate, 4 = high, and 5 = very high. EHMRG7
indicates Emergency Heart failure Mortality Risk
Grade for 7-day mortality; and EHMRG30-ST, Emergency Heart failure Mortality Risk Grade for
30-day mortality with ST-segment depression.
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Figure 3. Survival curve for time to 30-day
death by EHMRG30-ST risk category (1, 2, 3,
4, 5a, and 5b).
ED indicates emergency department; and
EHMRG30-ST, Emergency Heart failure Mortality
Risk Grade for 30-day mortality with ST-segment
depression.

Figure VI in the online-only Data Supplement divides our
prospective validation cohort according to tertiles of 7and 30-day risks simultaneously. Low risk patients are
low risk at both 7 and 30 days. Those considered high
risk could be at increased risk at either 7- or 30-day time
points (Figure VI in the online-only Data Supplement).

DISCUSSION
Downloaded from http://ahajournals.org by on June 22, 2022

In this study, we prospectively and externally validated a model for simultaneous prediction of both 7-day
and 30-day mortality for acute HF patients presenting to the emergency department. We found that the
EHMRG demonstrated high discrimination for both
7-day and 30-day mortality. One of the strengths of the
model was its ability to identify low-risk patients, with
no deaths at 7 days in the lowest 2 quintiles and no
deaths at 30 days in the lowest risk quintile. The models were also able to identify high-risk patients, with

mortality rates of 20% by 30 days after emergency department presentation. Physicians’ estimates of 7-day
mortality risk were assessed before any risk scores were
calculated, and these were modestly discriminative, but
EHMRG7 was superior to these estimates. When compared using net reclassification analysis, we found that
EHMRG7 substantially improved reclassification of risk
compared with physician estimates alone. Interestingly,
although EHMRG7 was superior to physician-estimated
risk alone, discrimination was numerically increased,
albeit nonsignificantly, when EHMRG7 and physicianestimated risk were combined.
The emergency department is the final common
pathway where patients with acutely decompensated
HF present. The decision to admit or discharge the
patient with acute HF is critically important; however,
these decisions have been made based on clinical judgment without the routine use of predictive risk models.22 Although physician-estimated risk has not been

Figure 4. Physician estimated risk vs
EHMRG7 risk score deciles.
EHMRG7 indicates Emergency Heart failure Mortality Risk Grade for 7-day mortality; and PER7,
physician-estimated risk of 7-day mortality.
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Table 4.

Validation of EHMRG for Acute Heart Failure

Survey Results
Option

N

n (%)
1983

Was furosemide provided
in ED?

Yes

Did patient improve with
treatment?*

Yes

567 (34.4%)†

Admit to hospital

615 (31.0%)

Admit after specialist
referral

956 (48.2%)

Discharge after
specialist referral

74 (3.7%)

Discharge home

326 (16.4%)

Cardiologist

829 (41.8%)

HF clinic

681 (34.3%)

Internal medicine clinic

140 (7.1%)

Family physician

441 (22.2%)

Plan for patient

If patient is discharged,
what type of follow-up
would you suggest?

1648 (83.1%)

HF indicates heart failure.
*Denominator = those who received furosemide.
†Judged clinically.
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formally studied in the acute hospital setting, a previous report found that physicians overestimated the risk
of ambulatory patients with advanced, chronic HF and
were unable to differentiate survival of perceived lowversus high-risk patients in the clinic setting.23 Inaccuracies in physicians’ predictions of prognosis have also
been reported in patients in whom outcomes occur stochastically, including acute stroke24 and length of stay in
the intensive care unit.25 Inaccuracies in prognostication
by physicians could potentially lead to low-risk hospital admissions and high-risk hospital discharges, which
could lead to postdischarge mortality.7
From the perspective of risk stratification, the present study provides real-world emergency department–
based clinical validation of the EHMRG models for 7-day
and 30-day mortality risk, which were originally derived
using large-scale chart review by highly trained nurse
abstractors.10,11 The EHMRG is distinct from other risk
assessment methods for acute HF. Many methods for
risk estimation have been published for chronic stable
HF patients in the ambulatory clinical setting.26–28 Relatively few prognostic scores have been validated in the
acute setting where patients present to the emergency
department and acute care decisions must be made
quickly, often without the availability of left ventricular
functional assessment or advanced cardiac imaging. A
recently published systematic review reported on other
models for acute HF, and found that they were limited
because of modest discriminative ability, high event
rates in the lowest-risk group, and exclusion of a large
proportion of potential patients.29–32 Furthermore, other
models included composite nonfatal events, which did
not account for competing risks.29–32 One model that
examined 30-day mortality was the MEESI-AHF (MultiCirculation. 2019;139:1146–1156. DOI: 10.1161/CIRCULATIONAHA.118.035509

Table 5. Predictors of Admission to Hospital (Versus Discharge From
ED)
Variable

Odds Ratio (95%CI)

P Value

1.14 (0.92, 1.42)

0.225

Univariate predictors
 Men
 Diuretics
reference

n/a

  Given, no improvement or
uncertain

  None

2.17 (1.57, 2.97)

<0.001

  Given, improved

0.46 (0.34, 0.63)

<0.001

 PER (%), per 1-SD

3.90 (2.55, 6.32)

<0.001

 EHMRG7 score, per 1-SD

2.21 (1.94, 2.53)

<0.001

1.25 (0.99, 1.59)

0.065

Multivariable predictors
 Men
 Diuretics
reference

n/a

  Given, no improvement or uncertain

  None

2.00 (1.43, 2.79)

<0.001

  Given, improved

0.40 (0.28, 0.55)

<0.001

 PER (%), per 1-SD

2.47 (1.71, 3.83)

<0.001

 EHMRG7 score, per 1-SD

2.08 (1.81, 2.40)

<0.001

EHMRG7 indicates Emergency Heart failure Mortality Risk Grade for 7-day
mortality; and PER, physician-estimated risk.

February 26, 2019

1153

ORIGINAL RESEARCH
ARTICLE

Survey Question

ple Estimation of risk based on the Emergency department Spanish Score in patients with AHF), a complex
model requiring knowledge of >20 variables including a separately calculated Barthel index.33 Although
the Barthel index was the most important part of the
MEESI-AHF model, the accuracy of self-report to determine the score has been questioned in the elderly,34
and it is not routinely assessed in the acute setting as
demonstrated by 28% missingness of this variable in
the MEESI-AHF cohort.33 Finally, with the exception of
the Ottawa Heart Failure Risk Scale,31 none of the above models have been validated externally and prospectively, nor have they been shown to perform better
than physician judgment.
The biological mechanisms conferring increased mortality risk for predictors such as blood pressure, heart rate,
and renal function have been previously described.10,11,35
Since the publication of our original derivation models,
studies have provided further links between the covariates in our models with acute HF mortality. Specifically,
the prognostic value of serum potassium concentrations
and the U-shaped association with risk, over the continuum of time, was demonstrated in Spanish and Danish
cohorts.36,37 The chronic use of metolazone was associated with in-hospital hypotension in the ASCEND-HF trial
(Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) and is indicative of relative
diuretic resistance, which are both predictors of later mortality.38,39 Finally, troponin elevation has been confirmed
as a predictor of mortality in acute HF.40–42 The current
study also provides insights potentially contributing to the
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observation that low-risk patients are often hospitalized
and high-risk patients are sometimes discharged.2,43 Specifically, physicians tended to overestimate the probability
of 7-day mortality in low-risk patients, while paradoxically
underestimating the probability in those at highest risk.
These findings have implications for the many patients
with acute HF who present to emergency departments
worldwide because estimation of prognosis underlies
many clinical decisions. Since EHMRG does not rely on advanced imaging and biomarkers with limited accessibility,
it enables prognostication in a wide range of healthcare
systems. A determination of low risk may be an important
consideration when deciding to discharge patients early
if they improve symptomatically with diuretic administration. Such patients could be followed rapidly in an ambulatory HF clinic where further investigations and medical
optimization could occur.44 Intermediate- or high-risk patients will likely require hospital admission, and those at
highest risk may potentially require more intensive monitoring during their hospital stay.45 Our findings suggest
that reliance on clinically judged risk estimates alone may
result in a potential mismatch, whereby many low-risk
patients are hospitalized or potentially unsafe discharges
from the emergency department might occur. Although
the EHMRG provides important prognostic information,
it does not supplant clinical decision-making. Instead,
EHMRG is 1 factor that complements other pragmatic aspects of the decision to admit or discharge patients from
hospital. These clinical factors include (but are not limited
to) ability for self-care, availability of social supports, multiple active medical issues requiring treatment simultaneously, comorbidities, functional status, and excessive congestion or limited mobility necessitating in-hospital care
provision. Finally, our study highlights the insights gained
by examining and comparing physician-estimated risk against prediction models, and provides an approach that
investigators can use in the validation of risk scores and
algorithms in the future.
Limitations of our study should be noted. Since the
current study was not an explicit clinical validation, physicians were not directed to use the EHMRG score to
make admission decisions. Therefore, we could not determine physician compliance with using the score or its
impact on hospitalization. Our study could not capture
the complex thought processes and patient-physician
exchanges that were involved in recommending hospital admission or discharge, of which physician-estimated
risk is but 1 component of the decision, nor could we rule
out the possibility that physicians subconsciously used
the score to make decisions despite being instructed
otherwise. Thus, the analyses of physician management
plan in relation to patients’ risk scores should be considered hypothesis-generating, and the actual reduction of
hospitalizations may be less pronounced than our estimates. Both of the above limitations would require an
implementation trial, recruiting patients prospectively

where admission–discharge decisions are based on the
EHMRG, to test the hypothesis of a beneficial effect on
decision-making and outcomes. This hypothesis will be
tested in the COACH trial (Comparison of Outcomes
and Access to Care for Heart failure) (URL: www.clinicaltrials.gov. Unique identifier: NCT02674438).44 EHMRG
was not designed to predict repeat emergency visits or
postdischarge hospitalizations, which occurred in 586
(29.6%) and 424 (21.4%) patients overall within 30
days after hospital separation. Because death is a competing risk for these nonfatal outcomes, our study may
represent the basis for future efforts to predict these
nonfatal outcomes. Because the EHMRG models were
designed for HF patients, the performance of the models could be adversely affected if applied to those without an emergency department diagnosis of HF. Finally,
our study excluded patients who were palliative and had
an advanced directive of a do-not-resuscitate order before arrival in the emergency department; these patients
are known to have higher mortality risk.46 Although palliative patients were never included in the original derivation of EHMRG7, they were included in a Spanish
prospective validation study, which found that risk was
stratified even among this higher-risk patient group.47
In conclusion, clinical characteristics at emergency
department presentation are highly predictive of 7-day
and 30-day mortality among patients with acute HF. A
mathematical combination of these predictors was superior to physician estimate of mortality, demonstrating
improved discrimination and risk reclassification. Although it has now been validated prospectively, EHMRG
should not be used alone to decide whether to admit
or discharge patients, but should still be used alongside
clinical judgment. Implementation testing followed by
broad use of the prospectively validated EHMRG risk algorithm may improve care efficiency of those at lower
risk and enhance safety by decreasing inappropriate
discharge of high risk patients.
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